Etodolac
Etodolac is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Etodolac; Generic name: ETODOLAC; Drug class: Nonsteroidal Anti-inflammatory Drug [EPC].
| Brand name | Etodolac |
|---|---|
| Generic name | ETODOLAC |
| Drug class | Nonsteroidal Anti-inflammatory Drug [EPC] |
| Manufacturer | A-S Medication Solutions |
| Used for | INDICATIONS AND USAGE Carefully consider the potential benefits and risks of etodolac tablets and other treatment options before deciding to use etodolac tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac tablets are indicated: For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain |
| Dosage | DOSAGE AND ADMINISTRATION Carefully consider the potential benefits and risks of etodolac tablets and other treatment options before deciding to use etodolac tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). After observing the response to initial therapy with etodolac tablets, the dose and frequency should be adjusted to suit an individual patient's needs. Dosage adjustment of etodolac tablets is generally not re |
| Warnings | WARNINGS CARDIOVASCULAR EFFECTS Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAI |
| Active ingredient(s) | ETODOLAC |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00125d63-d8d0-46c5-bdf1-80d2c85eda5a |